Xenon as a Component of Anesthetic Maintenance for Early Activation of Patients after Myocardial Revascularization
https://doi.org/10.15360/1813-9779-2009-4-38
Abstract
Objective: to make a complex analysis of the efficacy of xenon as the major agent in maintaining anesthesia during early activation of patients operated on under extracorporeal circulation for coronary heart disease. Subjects and methods. Forty-two patients aged 59±3 years were examined. A total of 3±0.2 coronary arteries were shunted. General anesthesia was induced and maintained by propofol and fentanyl under extracorporeal circulation. Anesthesia was maintained by xenon inhalation in the preperfusion and postperfusion periods. General anesthesia was combined with high (Th3—Th4) epidural anesthesia in 10 cases. Results. During xenon inhalation, the central hemodynamic parameters were maximally steady-state both before and after extracorporeal circulation. The coronary perfusion conditions estimated from the coronary perfusion gradients were stable. The study of the conditions for coronary perfusion and the values of myocardial demand showed the persistence of their balance (r=0.55—0.83; p<0.05). With the use of epidural anesthesia as a component of maintenance, there was a two-fold increase (p<0.05) in the use of sympathomimetic agents. Lower Pa02 after initiation of xenon inhalation and, accordingly, decreased Fi02 were not associated with worse Pa02/Fi02 and increased intrapulmonary blood shunting; there were no changes in blood oxygen-transport function. Emergence from anesthesia occurred 9±1.2 min after the termination of xenon delivery and failed to be accelerated when epidural anesthesia was applied. The latter could reduce the inhaled concentration of xenon from 59.2±0.5 to 51.5±0.5% (p<0.05) and the dosage of fentanyl from 2.9±0.15 to 2.1±0.26 ^g/kg/hr <p<0.°5). The use of xenon as a basic anesthetic has prospects during early activation after myocardial revascularization under extracorporeal circulation. The advantage of xenon is the absence of negative effects on central hemodynamics and the presence of conditions for coronary perfusion in patients with coronary heart disease. This mode of maintenance provides not only an effective anesthetic protection, but also emergence from anesthesia in the range of 3 to 25 minutes after the end of operations, which allows one to make an early activation in the operating suite in more than 90% of cases. Key words: xenon, xenon anesthesia, early activation after surgery under extracorporeal circulation, anesthesia in patients with coronary heart disease.
References
1. Буров Н. Е., Иванов Г. Г., Остапченко Д. А. и соавт.
2. Буров Н. Е., Потапов В. Н., Макеев Г. Н.Ксенон в анестезиологии. Клинико-экспериментальные исследования. М.: Пульс; 2000.
3. Hecker K. E., Horn N., BaumertJ.H. et al.Minimum alveolar concentration (MAC) of xenon in intubated swine. Br. J. Anaesth. 2004; 92 (3): 421—424.
4. Hettrick D. A., Pagel P. S., Kersten J. R. et al.Cardiovascular effects of xenon in isoflurane-anesthetized dogs with dilated cardiomyopathy. Anesthesiology 1998; 89 (5): 1166—1173.
5. Preckel B, Schlack W.Editoril III: xenon — cardiovascularly inert? Br. J. Anaesth. 2004; 92 (6): 786—789.
6. Preckel B, Schlack W., Heibel T., Rutten H.Xenon produces minimal haemodynamic effects in rabbit with chronically compromised left ventricular function. Br. J. Anaesth. 2002; 88 (2): 264—269.
7. Schmidt M., Marx T., Schirmer U. et al.Neuroprotective effects of xenon: a new agent for cardiac anaesthesia and intensive care medicine. Eighth meeting of Association for low flow anaesthesia. San Sebastian, 2004, session 3. Internet:www.Alfanaes.freeserve.co.uk/session043-1.htm
8. Wappler F., Rossaint R., BaumertJ. et al.Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anesthesiology 2007; 106 (3): 463—471.
9. Лазарев Н. В.Благородные газы. В кн: Вредные вещества в промышленности. М.: Химия; 1977. 7—
10. Cullen S. C., Gross E. G.The anesthetic properties of xenon in animals and human beings with additional observations on krypton. Science 1951; 113 (2942): 580—582.
11. Буачидзе Л. Н., Смольников В. П.Наркоз ксеноном у человека. Вестн. АМН СССР 1962; 8: 22—25.
12. Козлов И. А., Хубутия А. Ш., Воронин С. В. и др.Первый опыт анестезии ксеноном при операциях с искусственным кровообращением (ИК). Тезисы 7-й ежегодной сессии НЦССХ им. А. Н. Бакулева РАМН. Бюллетень НЦсСх им. А. Н. Бакулева РАМН. Сердечнососудистые заболевания 2003; 4 (6): 125.
13. Baumert J. H., Falter F., Eletr D. et al.Xenon anaesthesia may preserve cardiovascular function in patients with heart failure. Acta Anaesthesiol. Scand. 2005; 49 (6): 743—749.
14. Hofland J., Gultuna I., Tenbrinck R.Xenon anaesthesia for laparoscopic cholecystectomy in a patient with Eisenmenge’s syndrome. Br. J. Anaesth. 2001; 86 (6): 882—886.
15. GotoТ., Hanne P., Ishiguro Y. et al.Cardiovascular effects of xenon and nitrous oxide in patients during fentanyl-midazolam anaesthesia. Anaesthesia 2004; 59 (12): 1178—1183.
16. Lockwood G. G., Franks N. P., Downie N. A. et al.Feasibility and safety of delivering xenon to patients undergoing coronary artery bypass graft surgery while on cardiopulmonary bypass: Phase I Study. Anesthesiology 2006; 104 (3): 458—465.
17. Кожевников В. А., Сандриков В. А., Федулова С. В. и др.Динамика мозгового кровотока у больных ишемической болезнью сердца во время комбинированной ксеноновой анестезии при операциях ре-васкуляризации миокарда. Анестезиология и реаниматология 2006; 5: 25—28.
18. Руденко М. И., Пасько В. Г., Таубаев Б. М., Стец В. В.Опыт применения ксеноновой анестезии в главном военном госпитале им. акад. Н. Н.Бурденко. Клин. анестезиология и реаниматология 2006; 5: 58—64.
19. Dingley J., Findlay G. P., Foex B. A. et al.A closed xenon anesthesia delivery system. Anesthesiology 2001; 94 (1): 173—176.
20. Wilhelm S., Ma D., Maze M. B., Franks N.Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 2002; 96 (6): 1485—1491.
21. Ma D., Yang H., Lynch J. et al.Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology 2003; 98 (3): 690—698.
22. Picker O., Schindler A. W., Schwarte L. A. et al.Xenon increases total body oxygen consumption during isoflurane anaesthesia in dogs. Br. J. Anaesth. 2002; 88 (4): 546—554.
23. Stowe D. F., Rehmert G. C., Kwok W. M. et al.Xenon does not alter cardiac function or major cation currents in isolated guinea pig hearts or myocytes. Anesthesiology 2000; 92 (2): 516—522.
24. Weber N. C., Toma O., Wolter J. I. et al.The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC- and p38 MAPK. Br. J. Pharmacol. 2005; 144 (1): 123—132.
25. Calzia E., Stahl W., Handschuh T. et al.Continuous arterial pO2and pCO2measurements in swine during nitrous oxide and xenon elimination: prevention of diffusion hypoxia. Anesthesiology 1999; 90 (3): 829—834.
26. Chaney M. A.Epidural techniques for adult cardiac surgery. In: Regional anesthesia for cardiothoracic surgery. Chaney M. A. (ed.). Lippincott Williams & Wilkins; 2002. 59—81.
27. Horlocker T. T.Complications of spinal and epidural anesthesia. Anesthesiol. Clin. North Amer. 2000; 18 (2): 461—485.
28. Kratz C. D., Schirmer U., Weiss S. et al.Thoracic epidural anaesthesia as a part of a fast track concept for cardiac surgery. Appl. cardiopulmonary pathophysiol. 2007; 11 (1): 17—20.
Review
For citations:
Dzybinskaya Ye.V., Stepanova O.V., Kozlov I.A. Xenon as a Component of Anesthetic Maintenance for Early Activation of Patients after Myocardial Revascularization . General Reanimatology. 2009;5(4):38. (In Russ.) https://doi.org/10.15360/1813-9779-2009-4-38
Views:
1052
Email this article 